| Ovarian Cancer |
| 299- | ALA, | Cisplatin, | PacT, | Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 266- | ALA, | Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death |
| - | in-vitro, | Ovarian, | IGROV1 |
| 577- | Api, | PacT, | Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 273- | Api, | Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase |
| - | in-vivo, | Ovarian, | A2780S |
| 275- | Api, | Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3‑derived sphere-forming cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 1147- | ART/DHA, | Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 |
| - | vitro+vivo, | Ovarian, | HO-8910 | - | vitro+vivo, | Nor, | HUVECs |
| 1028- | ASA, | Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development |
| - | vitro+vivo, | Ovarian, | NA |
| 1363- | Ash, | doxoR, | Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | CaOV3 | - | in-vivo, | NA, | NA |
| 4660- | Ash, | Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells |
| - | in-vitro, | Ovarian, | NA |
| 4677- | Ash, | Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells |
| - | vitro+vivo, | Ovarian, | NA |
| 3157- | Ash, | Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass |
| - | in-vivo, | Ovarian, | A2780S |
| 4982- | ATV, | Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancer |
| - | in-vivo, | Ovarian, | NA |
| 1520- | Ba, | Baicalein Induces G2/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | TOV-21G |
| 1381- | BBR, | Rad, | Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3) |
| - | in-vitro, | Ovarian, | SKOV3 |
| 2710- | BBR, | Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 722- | Bor, | Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms |
| - | in-vitro, | Ovarian, | MDAH-2774 |
| 1297- | CA, | Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Deregulation of BCL2/BAX Genes |
| - | in-vitro, | Ovarian, | OV7 |
| 2791- | CHr, | Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction |
| - | in-vitro, | Ovarian, | OV90 |
| 952- | Cin, | Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U251 | - | in-vivo, | Ovarian, | SKOV3 |
| 1585- | Citrate, | Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Nor, | HEK293 |
| 1592- | Citrate, | Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | IGROV1 |
| 4776- | CoQ10, | Antitumor properties of Coenzyme Q0 against human ovarian carcinoma cells via induction of ROS-mediated apoptosis and cytoprotective autophagy |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 469- | CUR, | The inhibitory effect of curcumin via fascin suppression through JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 470- | CUR, | Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line |
| - | in-vitro, | Ovarian, | SKOV3 |
| 471- | CUR, | Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S |
| 472- | CUR, | Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | vitro+vivo, | Ovarian, | A2780S |
| 1874- | DCA, | Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | MDAH-2774 |
| 2169- | dietF, | Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy |
| - | Case Report, | Ovarian, | NA |
| 4681- | EGCG, | Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling |
| - | in-vitro, | Ovarian, | ES-2 |
| 1247- | EMD, | Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S |
| 947- | GA, | Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Melanoma, | A2780S | - | in-vitro, | Nor, | IOSE364 | - | Human, | NA, | NA |
| 1959- | GamB, | Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA | - | in-vivo, | NA, | NA |
| 1965- | GamB, | doxoR, | Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis |
| - | in-vitro, | Ovarian, | SKOV3 |
| 828- | GAR, | Cisplatin, | Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 4507- | GLA, | Effect of γ-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-453 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | GC, | NCI-N87 |
| 982- | LT, | Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19) |
| - | in-vitro, | Ovarian, | KGN |
| 1317- | LT, | Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2 |
| - | vitro+vivo, | Ovarian, | PA1 |
| 2929- | LT, | Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention |
| - | in-vitro, | Ovarian, | NA |
| 1714- | Lyco, | Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load |
| - | in-vitro, | Ovarian, | OV-MZ-6 | - | in-vivo, | NA, | NA |
| 2542- | M-Blu, | In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death |
| - | in-vitro, | Ovarian, | OV1369 | - | in-vitro, | Ovarian, | OV1946 | - | in-vitro, | Nor, | ARPE-19 |
| 2535- | M-Blu, | SDT, | Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic action |
| - | in-vitro, | Ovarian, | HO-8910 |
| 2257- | MF, | HPT, | HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer |
| - | in-vitro, | Ovarian, | NA |
| 3500- | MF, | Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress |
| - | in-vitro, | Ovarian, | SKOV3 |
| 777- | Mg, | Biodegradable Mg Implants Suppress the Growth of Ovarian Tumor |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 930- | MushShi, | Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation |
| - | in-vitro, | Ovarian, | NA |
| 1128- | Myr, | Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer |
| - | vitro+vivo, | Ovarian, | NA |
| 1805- | NarG, | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | NA |
| 1271- | NCL, | Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 1268- | NCL, | carbop, | Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer |
| - | in-vitro, | Ovarian, | NA |
| 4959- | PEITC, | Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment |
| - | in-vitro, | Ovarian, | NA |
| 4954- | PEITC, | Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 4951- | PEITC, | ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis |
| - | in-vitro, | Ovarian, | PA1 | - | in-vitro, | Ovarian, | SKOV3 |
| 4943- | PEITC, | Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 1237- | PTS, | Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade |
| - | in-vitro, | Ovarian, | SKOV3 |
| 50- | QC, | Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer |
| - | vitro+vivo, | Ovarian, | A2780S |
| 51- | QC, | Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines |
| - | in-vitro, | Ovarian, | SKOV3 |
| 916- | QC, | Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells |
| - | Review, | Ovarian, | NA |
| 323- | Sal, | SNP, | Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Ovarian, | A2780S |
| 1707- | Se, | A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers |
| - | in-vivo, | Ovarian, | NA | - | in-vivo, | BC, | NA |
| 1702- | Se, | Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women |
| - | Human, | Ovarian, | NA |
| 1701- | Se, | An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer |
| - | Human, | Ovarian, | NA |
| 4718- | Se, | High-Dose Selenium Induces Ferroptotic Cell Death in Ovarian Cancer |
| - | in-vitro, | Ovarian, | NA |
| 4749- | Se, | Chemo, | antiOx, | Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy |
| - | Trial, | Ovarian, | NA |
| 4747- | Se, | Chemo, | antiOx, | Phase I trial of selenium plus chemotherapy in gynecologic cancers |
| - | Trial, | Ovarian, | NA |
| 2356- | SK, | ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment |
| - | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Ovarian, | OV90 | - | in-vivo, | NA, | NA |
| 1343- | SK, | Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | A2780S |
| 322- | SNP, | Cisplatin, | Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 397- | SNP, | GEM, | Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment |
| - | in-vitro, | Ovarian, | A2780S |
| 358- | SNP, | Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 4539- | SNP, | VitC, | Citrate, | Investigating the Anti-cancer Potential of Silver Nanoparticles Synthesized by Chemical Reduction of AgNO3 Using Trisodium Citrate and Ascorbic Acid |
| - | in-vitro, | Nor, | L929 | - | in-vitro, | Ovarian, | SKOV3 |
| 4563- | SNP, | Rad, | Silver nanoparticles enhance neutron radiation sensitivity in cancer cells: An in vitro study |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | Melanoma, | A431 |
| 4389- | SNP, | Graphene Oxide-Silver Nanocomposite Enhances Cytotoxic and Apoptotic Potential of Salinomycin in Human Ovarian Cancer Stem Cells (OvCSCs): A Novel Approach for Cancer Therapy |
| - | in-vitro, | Ovarian, | NA |
| 1202- | Tb, | The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 1936- | TQ, | Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line |
| - | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Nor, | WRL68 |
| 5020- | UA, | Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway |
| - | in-vitro, | Ovarian, | NA |
| 300- | VitC, | ALA, | Combination of High-Dose Parenteral Ascorbate (Vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect But Increased Toxicity in Preclinical Cancer Models |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Ovarian, | PANC1 | - | in-vitro, | Pca, | PC3 |
| 3138- | VitC, | The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | GBM, | U251 |
| 3133- | VitC, | Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 1222- | Z, | Zinc regulates primary ovarian tumor growth and metastasis through the epithelial to mesenchymal transition |
| - | in-vitro, | Ovarian, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:20 Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid